User menu

Should chronic hepatitis B be treated as early as possible?

Bibliographic reference Hulstaert, Frank ; Schwierz, Christoph ; Nevens, Frederik ; Thiry, Nancy ; Gamil, Mohamed ; et. al. Should chronic hepatitis B be treated as early as possible?. In: International Journal of Technology Assessment in Health Care, Vol. 29, no.1, p. 35-41 (2013)
Permanent URL http://hdl.handle.net/2078.1/136693
  1. , EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection, 10.1016/j.jhep.2012.02.010
  2. Colombo Massimo, Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons, 10.1016/s1590-8658(10)60520-8
  3. Fattovich Giovanna, Bortolotti Flavia, Donato Francesco, Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors, 10.1016/j.jhep.2007.11.011
  4. McMahon Brian J., The natural history of chronic hepatitis B virus infection, 10.1002/hep.22898
  5. Acta Gastroenterol Belg., 70, 389 (2007)
  6. Spackman D Eldon, Veenstra David L, A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B : , 10.2165/00019053-200826110-00006
  7. VEENSTRA D. L., SPACKMAN D. E., BISCEGLIE A., KOWDLEY K. V., GISH R. G., Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis : EVALUATING ANTI-VIRAL THERAPY IN HBEAG-NEGATIVE CHB, 10.1111/j.1365-2036.2008.03691.x
  8. Arnold Elizabeth, Yuan Yong, Iloeje Uchenna, Cook Greg, Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B, 10.1007/bf03256136
  9. Exp Clin Hepatol., 4, 20 (2008)
  10. Braz J Infect Dis., 12, 368 (2008)
  11. Buti Maria, Brosa Max, Casado Miguel A., Rueda Magdalena, Esteban Rafael, Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B, 10.1016/j.jhep.2009.04.013
  12. Veenstra David L., Sullivan Sean D., Lai Ming-Yang, Lee Chuan-Mo, Tsai Chia-Ming, Patel Kavita K., HBeAg-Negative Chronic Hepatitis B: Cost-Effectiveness of Peginterferon Alfa-2a Compared to Lamivudine in Taiwan, 10.1111/j.1524-4733.2007.00221.x
  13. Lacey L. F., Gane E., The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore, 10.1111/j.1365-2893.2007.00865.x
  14. Dakin Helen, Bentley Anthony, Dusheiko Geoff, Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B, 10.1111/j.1524-4733.2010.00782.x
  15. Levy Adrian R., Kowdley Kris V., Iloeje Uchenna, Tafesse Eskinder, Mukherjee Jayanti, Gish Robert, Bzowej Natalie, Briggs Andrew H., The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons, 10.1111/j.1524-4733.2007.00297.x
  16. Post S. E., Sodhi N. K., Peng C.-h., Wan K., Pollack H. J., A Simulation Shows That Early Treatment Of Chronic Hepatitis B Infection Can Cut Deaths And Be Cost-Effective, 10.1377/hlthaff.2008.0905
  17. Veldhuijzen Irene K., Toy Mehlika, Hahné Susan J.M., De Wit G. Ardine, Schalm Solko W., de Man Robert A., Richardus Jan Hendrik, Screening and Early Treatment of Migrants for Chronic Hepatitis B Virus Infection Is Cost-Effective, 10.1053/j.gastro.2009.10.039
  18. Eckman Mark H., Kaiser Tiffany E., Sherman Kenneth E., The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States, 10.1093/cid/cir199
  19. Iloeje Uchenna H., Yang Hwai–I., Su Jun, Jen Chin–Lan, You San–Lin, Chen Chien–Jen, Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load, 10.1053/j.gastro.2005.11.016
  20. Chen Chien-Jen, Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level, 10.1001/jama.295.1.65
  21. Croagh Catherine M. N., Bell Sally J., Slavin John, Kong Yu X. G., Chen Robert Y, Locarnini Stephen, Desmond Paul V, Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B : Fibrosis risk in hepatitis B, 10.1111/j.1478-3231.2010.02267.x
  22. Kobashi Haruhiko, Miyake Yasuhiro, Ikeda Fusao, Yasunaka Tetsuya, Nishino Ken, Moriya Akio, Kubota Jyunichi, Nakamura Shinichiro, Takaki Akinobu, Nouso Kazuhiro, Yamada Gotaro, Yamamoto Kazuhide, Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine : HCC development in NA-treated CHB, 10.1111/j.1872-034x.2011.00785.x